Low-dose Mitomycin C Trabeculectomy In Patients With Advanced Glaucoma.

dc.creatorCosta, V P
dc.creatorComegno, P E
dc.creatorVasconcelos, J P
dc.creatorMalta, R F
dc.creatorJosé, N K
dc.date1996-Jun
dc.date2015-11-27T12:18:45Z
dc.date2015-11-27T12:18:45Z
dc.date.accessioned2018-03-29T00:51:50Z
dc.date.available2018-03-29T00:51:50Z
dc.identifierJournal Of Glaucoma. v. 5, n. 3, p. 193-9, 1996-Jun.
dc.identifier1057-0829
dc.identifier
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/8795759
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/193924
dc.identifier8795759
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1294157
dc.descriptionThe purpose of this study was to analyze the efficacy and safety of low-dose (0.2 mg/ml) intraoperative mitomycin C in primary trabeculectomy. Twenty-eight eyes of 28 patients with advanced primary open-angle glaucoma undergoing primary trabeculectomy were randomized to either mitomycin C (0.2 mg/ml) or saline solution intraoperatively for 3 min. Intraocular pressure was measured at 1 day; 1 week; 1, 3, and 6 months postoperatively; and at the final visit. Mean follow-up was 17.0 +/- 5.6 months for the mitomycin C group and 15.7 +/- 5.1 months for the control group. Mean intraocular pressures were significantly lower in the treated group on the first postoperative day (p = 0.021), at the 6-month interval (p = 0.001), and at the final visit (p = 0.001). At the last follow-up examination, intraocular pressure was < or = 15 mm Hg in 12 (85.7%) of the mitomycin C-treated eyes and in four (28.6%) of the control eyes (p = 0.002). Life table analysis showed a significantly higher probability of intraocular pressure control in the mitomycin C group than in the control group (p = 0.0065). Choroidal effusion was observed in five (35.7%) treated eyes and two (14.3%) control eyes, whereas shallow anterior chamber were present in five (35.7%) treated eyes and one control eye (7.1%). Despite inducing a higher short-term complication rate, low-dose mitomycin C may be an alternative in the treatment of eyes with advanced glaucomatous damage requiring low final intraocular pressures.
dc.description5
dc.description193-9
dc.languageeng
dc.relationJournal Of Glaucoma
dc.relationJ. Glaucoma
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAged
dc.subjectAlkylating Agents
dc.subjectDose-response Relationship, Drug
dc.subjectFemale
dc.subjectGlaucoma
dc.subjectHumans
dc.subjectIntraocular Pressure
dc.subjectIntraoperative Care
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMitomycin
dc.subjectOphthalmic Solutions
dc.subjectPostoperative Complications
dc.subjectSurvival Analysis
dc.subjectTrabeculectomy
dc.titleLow-dose Mitomycin C Trabeculectomy In Patients With Advanced Glaucoma.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución